Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

IMPORTANCE Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. OBJECTIVE To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. DESIGN, SETTING, AND PARTICIPANTS A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. EXPOSURES Presence of a law establishing a medical cannabis program in the state. MAIN OUTCOMES AND MEASURES Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. RESULTS Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P = .002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P = .01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P = .04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P = .02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P = .008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P < .001). In secondary analyses, the findings remained similar. CONCLUSIONS AND RELEVANCE Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

[1]  Leonard J. Paulozzi,et al.  Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. , 2011, MMWR. Morbidity and mortality weekly report.

[2]  K. Mann,et al.  Low efficacy of non‐opioid drugs in opioid withdrawal symptoms , 2005, Addiction biology.

[3]  Nilay D Shah,et al.  Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010 , 2013, Medical care.

[4]  C. Heather Ashton,et al.  Pharmacology and effects of cannabis: A brief review , 2001, British Journal of Psychiatry.

[5]  A. J. Clark,et al.  Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. , 2003, Journal of pain and symptom management.

[6]  L. Fiellin,et al.  Previous use of alcohol, cigarettes, and marijuana and subsequent abuse of prescription opioids in young adults. , 2013, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[7]  J. Astemborski,et al.  Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. , 2011, Addictive behaviors.

[8]  Caleb J Banta-Green,et al.  “Hooked on” Prescription-Type Opiates Prior to Using Heroin: Results from a Survey of Syringe Exchange Clients , 2012, Journal of psychoactive drugs.

[9]  Eric L. Sevigny,et al.  Marijuana liberalization policies: why we can’t learn much from policy still in motion. , 2014, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[10]  S. Galea,et al.  Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. , 2012, Drug and alcohol dependence.

[11]  Christopher M. Jones,et al.  CDC Grand Rounds: Prescription Drug Overdoes - A U.S. Epidemic , 2012 .

[12]  Grant T. Baldwin,et al.  CDC grand rounds , 2012 .

[13]  N. Martin,et al.  Escalation of drug use in early-onset cannabis users vs co-twin controls. , 2003, JAMA.

[14]  Christopher L Skeels,et al.  Mostly Harmless Econometrics: An Empiricist’s Companion , 2011 .

[15]  M. Valenstein,et al.  Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths , 2012 .

[16]  D. Kandel,et al.  Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. , 1984, American journal of public health.

[17]  G. Friedman,et al.  Marijuana use and mortality. , 1997, American journal of public health.

[18]  H. Surratt,et al.  Effect of abuse-deterrent formulation of OxyContin. , 2012, The New England journal of medicine.

[19]  S. Watson,et al.  Marijuana and Medicine: Assessing the Science Base , 1999 .

[20]  E. V. Van Bockstaele,et al.  Impact of cannabis use during stabilization on methadone maintenance treatment. , 2013, The American journal on addictions.

[21]  D. Kandel.  Does marijuana use cause the use of other drugs? , 2003, JAMA.

[22]  N. Benowitz,et al.  Cannabinoid–Opioid Interaction in Chronic Pain , 2011, Clinical pharmacology and therapeutics.

[23]  Daniel Rosenblum,et al.  Intertwined Epidemics: National Demographic Trends in Hospitalizations for Heroin- and Opioid-Related Overdoses, 1993–2009 , 2013, PloS one.

[24]  W. A. Chambers,et al.  Pharmacological actions and therapeutic uses of cannabis and cannabinoids , 2001, Anaesthesia.

[25]  L J Horwood,et al.  Early onset cannabis use and psychosocial adjustment in young adults. , 1997, Addiction.

[26]  E. V. Bockstaele,et al.  Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal , 2013, Neuroscience.

[27]  Karin A Mack,et al.  Pharmaceutical overdose deaths, United States, 2010. , 2013, JAMA.

[28]  Joshua D. Angrist,et al.  Mostly Harmless Econometrics: An Empiricist's Companion , 2008 .

[29]  B. Psaty,et al.  Opioid Prescriptions for Chronic Pain and Overdose , 2010, Annals of Internal Medicine.

[30]  M. Lynch,et al.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. , 2011, British journal of clinical pharmacology.

[31]  G. Di Chiara,et al.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.

[32]  Patrick Richard,et al.  The economic costs of pain in the United States. , 2012, The journal of pain : official journal of the American Pain Society.

[33]  Nora D Volkow,et al.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.